Sort
30,917 grants matching “tumor microenvironment”
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity
$348,892Taslim A Al-Hilal · University Of Texas El Paso · R01 · FY2022 · CA
Precision Interception of Aggressive Prostate Cancer in African American Men
$348,847Franklin W Huang · Dana-Farber Cancer Inst · P20 · FY2020 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2021 · CA
NOVEL SMALL MOLECULE INHIBITION OF DDR2 TO PREVENT BREAST CANCER METASTASIS
$348,844Gregory Longmore · Washington University · R01 · FY2016 · CA
G-CSF inhibition as a colorectal cancer therapy
$348,844Ellen J. Beswick · University Of Utah · R01 · FY2018 · CA
Mitochondrial lateral transfer during metastasis
$348,844Minna Roh · University Of Utah · R37 · FY2022 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2022 · CA
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
$348,844Michael W Deininger · University Of Utah · R01 · FY2020 · CA
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA
$348,844Jacqueline E. Payton · Washington University · R01 · FY2015 · CA
Mitochondrial lateral transfer during metastasis
$348,844Minna Roh · Utah State Higher Education System--University Of Utah · R37 · FY2025 · CA
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA
$348,844Jacqueline E. Payton · Washington University · R01 · FY2017 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2018 · CA
NOVEL SMALL MOLECULE INHIBITION OF DDR2 TO PREVENT BREAST CANCER METASTASIS
$348,844Gregory Longmore · Washington University · R01 · FY2017 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2016 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2017 · CA
NOVEL SMALL MOLECULE INHIBITION OF DDR2 TO PREVENT BREAST CANCER METASTASIS
$348,844Gregory Longmore · Washington University · R01 · FY2015 · CA
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA
$348,844Jacqueline E. Payton · Washington University · R01 · FY2016 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2020 · CA
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMA
$348,844Jacqueline E. Payton · Washington University · R01 · FY2018 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2020 · CA
Mitochondrial lateral transfer during metastasis
$348,844Minna Roh · University Of Utah · R37 · FY2021 · CA
Obesity, inflammation and breast cancer
$348,842Weizhou Zhang · University Of Florida · R01 · FY2020 · CA
Molecular Epidemiologic Study of Breast Cancer
$348,840Vanderbilt University · R01 · FY2005 · CA
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
$348,835Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2021 · CA
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
$348,832Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2020 · CA